JPRN-UMIN000005181已完成1 期
Phase I/II study of Irinotecan and Erlotinib in patients for EGFR mutation negative previously treated non-small-cell lung cancer. - Phase I/II study of Irinotecan and Erlotinib in patients for EGFR mutation negative previously treated non-small-cell lung cancer.(OULCSG-1101)
Osaka Univ. Hospital Respiratory Medicine0 个研究点目标入组 27 人开始时间: 2011年3月3日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Diagnosed mutation or heterozygosity of UGT1A1*6/*28. (2)Serious drug allergy. (3)Interstitial pneumonia documented obviously in chest X ray. (4)massive pleural or pericardial effusion ,or ascites. (5)active severe infections. (6)Active synchronous malignancies. (7)Pregnant or beeast-feeding woman or patient who doesn't agree to contraception. (8)Serious psychological disease. (9)brain metastasis. (10)Clinically significant heart disease (myocardial infarction within 12 months, etc.). (11)Uncontrolled diabetes mellitus. (12)Watery diarrhea. (13)Ileus or bowel obstruction. (14)bleeding that requires medication or transfusion. (15)Clinically significant complication. (16)Investigator's judgement.
研究者
相似试验
已完成
不适用
Phase I-II Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for Non-Small Cell Lung CancerErlotinib Failure for Non-Small Cell Lung CancerJPRN-UMIN000003102Department of Thoracic Medical Oncoligy CancernInstitute Hospital Japanese foundation for cancer reseach43
已完成
1 期
Phase I Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for EGFR Mutations Non-Small Cell Lung CancerJPRN-UMIN000005873Hamamatsu University School of Medicine, First Department of Surgery1
已完成
1 期
Phase I/II Study of Irinotecan and Gemcitabine in Pediatric, adolescent and Young Adult Patients with Relapsed or Refractory Solid TumorsRelapse/refractory pediatric/AYA solid tumorJPRN-UMIN000020144Group for "combination chemotherapies for refractory Adolescent and Young Adult solid tumors "10
招募中
1 期
A phaseI/II study of Erlotinib/Carboplatin/Pemetrexed/Bevacizumab in chemotherapy-naive patients with EGFR mutation positive advanced non-squamous non-small-cell lung canceron-Small-Cell Lung CancerJPRN-UMIN000013202Kansai Medical University Hirakata Hospital35
进行中（未招募）
不适用
A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapy - phase II erlotinib-sorafenib in advanced NSCLCAdvanced non small cell lung cancerEUCTR2007-004625-14-NLVU University Medical Centre48